Aspire Biopharma Holdings, Inc. operates as a biopharmaceutical company that engages in developing and marketing a disruptive technology for drugs, nutraceuticals & supplements. The company develops and markets a technology for novel delivery mechanisms for FDA approved drugs, nutraceuticals, and supplements. The company has developed and acquired technologies that are a Novel Soluble Formulation which address emergencies and drug efficacy, dosage management, and response time. Its Sublingual Aspirin Product, which addresses cardiology emergencies and pain management, is a granular or powder formulation of a soluble, Ph-neutral, fast-acting aspirin. The company also has numerous pharmaceutical and nutraceutical applications under development in various areas, including but not limited to a Viagra/Cialis combination product which is faster acting, requiring decreased dosages with the benefit of a longer half-life, various bi-hormonal drugs such as testosterone, estrogen and weight loss drugs, and thyroid drugs, as well as various supplements including a rapid-absorbing pre-workout and a melatonin sleep aid.
Follow-Up Questions
Aspire Biopharma Holdings Inc 的 CEO 是誰?
Mr. Surendra Ajjarapu 是 Aspire Biopharma Holdings Inc 的 Executive Chairman of the Board,自 2023 加入公司。
ASBP 股票的價格表現如何?
ASBP 的當前價格為 $0.4403,在上個交易日 decreased 了 0%。
Aspire Biopharma Holdings Inc 的主要業務主題或行業是什麼?
Aspire Biopharma Holdings Inc 屬於 Pharmaceuticals 行業,該板塊是 Health Care